Skip to main content
. 2022 Oct 10;15:7739–7750. doi: 10.2147/IJGM.S382757

Table 1.

Patients Characteristics and Pathologic Outcomes in the Groups

Characteristics Group QG (n=119) Group GA (n=112) P value
Age, (year) 64.3±8.6 62.3±9.2 0.10
Male sex, n (%) 72 (60.5) 63 (56.3) 0.51
Weight (kg) 67.2±11.1 64.6±10.3 0.06
BMI (kg/m2) 22.0±2.3 21.7±1.8 0.27
ASA grade, n (%)
 I 11 (9.2) 9 (8.0) 0.19
 II 83 (69.8) 89 (79.5)
 III 25 (21.0) 14 (12.5)
Hemoglobin (g/L) 124.3±20.5 125.4±19.2 0.66
Sevoflurane (mL) 101.5±15.8 105.0±13.2 0.07
Propofol (mg) 1100.8±852.5 994.6±251.1 0.21
Duration of anesthesia (min) 208.0 ± 28.9 206.2 ± 27.5 0.63
Duration of surgery (min) 180.5 ± 28.5 178.3 ± 29.6 0.58
Intraoperative blood loss (mL) 89.9 ±33.7 98.1 ±35.7 0.08
Urine volume (mL) 135.5±34.5 128.8±39.8 0.17
Tumor size, cm, n (%) 119 112
 ≤5 78 (65.5) 78 (69.6) 0.51
 >5 41 (34.5) 34 (30.4)
Tumor location, n (%)
 Proximal stomach 19 (16.0) 20 (17.9) 0.55
 Middle stomach 32 (26.9) 36 (32.1)
 Distal stomach 68 (57.1) 56 (50.0)
Operative procedure, n (%)
 Total gastrectomy 72 (60.5) 61 (54.5) 0.38
 Distal gastrectomy 46 (38.7) 51 (45.5)
 Esophagogastric resection 1 (0.8) 0
c T stage, n (%)
 cT1 29 (24.4) 33 (29.5) 0.51
 cT2 39 (32.8) 40 (35.7)
 cT3 46 (38.6) 37 (33.0)
 cT4 5 (4.2) 2 (1.8)
Lymphadenectomy, n (%)
 D1 43 (36.1) 45 (40.2) 0.53
 D2 76 (63.9) 67 (59.8)
pTNM stage n (%)
 I 23 (19.3) 22 (19.6) 0.36
 I 53 (44.5) 59 (52.7)
 III 43 (36.1) 31 (27.7)
Treatment regime, n (%)
 Surgery only 33 (27.7) 35 (31.3) 0.72
 Surgery &chemotherapy 81 (68.1) 74 (66.0)
 Other treatment 5 (4.2) 3 (2.7)

Notes: The data are given as mean ± SD or n (%). Quantitative data were compared by independent-sample t test; Categorical data were compared by chi-squared test.